BCDA241115C2500
- 0.05
- 0.000.00%
BioCardia Newsroom
BioCardia Shares Are Trading Higher. The Company Reported Q3 Financial Results.
BioCardia's Strong Q3 Performance and Strategic Trials Drive Buy Rating
10-Q: Quarterly report
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript Summary
BioCardia GAAP EPS of -$0.61 Beats by $0.58
BioCardia 3Q Rev $0.00 >BCDA
BioCardia 3Q Loss/Shr 61c >BCDA
Press Release: BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
Earnings Scheduled For November 13, 2024
Earnings Preview: BioCardia to Report Financial Results Post-market on November 13
$BioCardia(BCDA.US)$ is scheduled to release its financial results post-market on November 13 ET. Earnings PreviewAnalysts estimate $BioCardia(BCDA.US)$ to post revenue of USD200.00K for 2024Q3,
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
BioCardia Analyst Ratings
Promising Outlook for BioCardia With Advancements in CardiAMP HF Program and Personalized Treatment Approach
Express News | BioCardia Inc - Results on Track for Top Line Release in Q1 2025
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
Express News | BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
12 Health Care Stocks Moving In Friday's Pre-Market Session
BioCardia Regains Full Compliance With Nasdaq Listing Requirements